InvestorsHub Logo
Followers 13
Posts 559
Boards Moderated 0
Alias Born 12/31/2012

Re: None

Saturday, 06/09/2018 6:37:47 PM

Saturday, June 09, 2018 6:37:47 PM

Post# of 2833
"CR/CRi/CRp for the dose ATNM plans to move forward with into Phase 2 (2x2 uCi/kg) in patients with low peripheral blast burden was 50%, matching the impressive data from Celator's VYXEOS at 48% reported in March 2016. As a reminder, JAZZ acquired Celator for $1.5 Billion in June 2016."

Not new but definitely a solid reminder of ATNM's potential.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ATNM News